Simplify Logo

Full-Time

Research Associate

RNA Process Development

Posted on 8/7/2024

Verve Therapeutics

Verve Therapeutics

201-500 employees

Developing gene editing therapies for heart disease

Hardware
Biotechnology
Healthcare

Entry, Junior

Boston, MA, USA

Category
Lab & Research
Life Sciences
Required Skills
Communications
Data Analysis
Requirements
  • B.S or M.S. in biological sciences, chemistry, or biomedical/chemical engineering, with 0-5 years of relevant industry experience is preferred.
  • Knowledge of nucleic acid and or biologics process development is preferred
  • Experience in downstream process development is ideal
  • Experience with practices and equipment used in process development of nucleic acids; including execution of preparative chromatography processes using an Akta Avant, and TFF is strongly preferred
  • Knowledge of analytical methods commonly used for nucleic acid is preferred; including fluorescence, capillary gel electrophoresis, analytical HPLC and ELISA based techniques
  • Attention to detail, critical analysis of data and troubleshooting abilities
  • Good writing and communication skills; ability to understand and communicate scientific information
Responsibilities
  • Plan and execute experiments at bench scale to support process development, scale up, and optimization of Verve’s mRNA drug substance manufacturing process.
  • Carefully execute a wide range of experiments to assist in establishing a science-based understanding of mRNA technology, process development and process scale-up.
  • Perform routine analytics to support understanding of RNA technology and processes including but not limited to fluorescence, HPLC and ELISA based techniques.
  • Opportunity to collaborate with cross-functional analytical development, tech transfer, external manufacturing as well as facility and operations colleagues.
  • Write protocols, perform experiments, organize and analyze data, interpret results, record experiments in an electronic lab notebook, and summarize work in presentations and technical reports.
  • Maintain a safe and high performing laboratory by ordering supplies, making buffers and reagents, caring for laboratory equipment and supporting continuous improvement initiatives related to lab operations.
  • Other duties as assigned.

Verve Therapeutics is developing single-course gene editing medicines to address cardiovascular disease, with a focus on precision genetic editing technologies to lower LDL cholesterol and triglyceride levels. Their lead program, VERVE-101, targets heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Company Stage

IPO

Total Funding

$419.3M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

5%

1 year growth

5%

2 year growth

40%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant financial backing, including a $63 million Series A2 financing and $60 million from Eli Lilly, positions Verve for robust R&D and clinical trial activities.
  • The potential for a 'one-and-done' treatment for cardiovascular diseases could revolutionize the field and offer a high-impact, life-saving solution.
  • Early-stage success and strategic partnerships could lead to lucrative licensing deals and further investment opportunities.

What critics are saying

  • The clinical-stage nature of Verve's therapies means they are still years away from potential market approval, posing a long-term risk.
  • The recent stock price drop following a public offering indicates market volatility and potential investor uncertainty.

What makes Verve Therapeutics unique

  • Verve Therapeutics focuses on gene-editing therapies specifically for cardiovascular diseases, setting it apart from other CRISPR-based companies that target a broader range of conditions.
  • Their 'one-and-done' gene-editing approach aims to provide a single, curative treatment, which is a significant advantage over traditional, ongoing therapies.
  • Partnerships with major pharmaceutical companies like Eli Lilly enhance their credibility and provide substantial financial and research support.
INACTIVE